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A B S T R A C T
SL-1-39 [1-(4-chloro-3-methylphenyl)-3-(4-nitrophenyl)thiourea] is a new flexible heteroarotinoid (Flex-Het)
analog derived from the parental compound, SHetA2, previously shown to inhibit cell growth across multiple
cancer types. The current study aims to determine growth inhibitory effects of SL-1-39 across the different
subtypes of breast cancer cells and delineate its molecular mechanism. Our results demonstrate that while SL-1-
39 blocks cell proliferation of all breast cancer subtypes tested, it has the highest efficacy against HER2+ breast
cancer cells. Molecular analyses suggest that SL-1-39 prevents S phase progression of HER2+ breast cancer cells
(SKBR3 and MDA-MB-453), which is consistent with reduced expression of key cell-cycle regulators at both the
protein and transcriptional levels. SL-1-39 treatment also decreases the protein levels of HER2 and pHER2 as
well as its downstream effectors, pMAPK and pAKT. Reduction of HER2 and pHER2 at the protein level is
attributed to increased lysosomal degradation of total HER2 levels. This is the first study to show that a flexible
heteroarotinoid analog modulates the HER2 signaling pathway through lysosomal degradation, and thus further
warrants the development of SL-1-39 as a therapeutic option for HER2+ breast cancer.
1. Introduction
The human epithelial receptor 2 (HER2 or erbb2) is a member of the
epidermal growth factor receptor (EGFR) family of receptor tyrosine
kinases that act through the EGF signaling cascade [1,2]. Approxi-
mately 20% of breast cancers overexpress HER2 and consequently, are
referred to as HER2-positive (HER2+) breast cancer [3–6]. The dys-
regulation of the HER2/EGFR pathway has been shown to result in
uncontrolled growth that can contribute to cancer progression [7,8].
The phosphorylation of the HER2 receptor dimers subsequently acti-
vates several downstream pathways, including the PI3K (phosphatidy-
linositol-3-kinase)/Akt (protein kinase B) pathway and the Ras-Raf
(rapidly accelerated fibrosarcoma)-MAPK (mitogen-activated protein
kinases) pathway [2,9]. These two pathways further modulate cell
proliferation, migration, angiogenesis, invasion, apoptosis and other
cellular processes [10,11]. Interestingly, unlike other EGFR members,
HER2 does not have a specific ligand binding domain and therefore is
constitutively active [12]. As a result, HER2 easily interacts with other
activated EGFR receptors, making HER2 the preferred dimerization
partner for these receptors and consequently an ideal target for breast
cancer therapies [13–15].
Amongst the newest cancer therapies being developed are flexible
heteroarotinoids (Flex-Hets), which are derived from retinoids and
possess promising anti-cancer activity [16–19]. Studies have shown
that one of the first Flex-Hets developed, SHetA2, inhibits growth of the
National Cancer Institute's panel of 60 human tumor cell lines by reg-
ulating apoptosis, cell growth, differentiation and angiogenesis
[17,19–21]. However, compared to most drugs, SHetA2 has higher li-
pophilicity (logP=7.09) [22] which may limit its bioavailability [23].
Therefore, a 2nd generation of Flex-Hets was designed and synthesized
to retain the anti-cancer activity of SHetA2 but with lower lipophilicity
[22].
The current study aims to investigate the effects of SL-1-39— a
promising 2nd generation analog of SHetA2— on breast cancer cell
growth. This is the first study to show that a flexible heteroarotinoid
blocks HER2+ breast cancer cell growth by disrupting the EGFR/HER2
pathway. In particular, we demonstrate that SL-1-39 treatment in
HER2+ breast cancer cells leads to lysosomal degradation of HER2.
Our results strongly support further development of SL-1-39 as a ther-
apeutic option for HER2+ breast cancer and underscore the importance
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of studying the effects of flexible heteroarotinoids, like SL-1-39, on
other cancer types that overexpress HER2 and/or members of the EGFR
family.
2. Materials and methods
2.1. Cell culture
Breast cancer cell lines MCF-7, T47D, SKBR3, MDA-MB-453, BT474,
MDA-MB-468, MDA-MB-231, HCC1806 and BT20 and the normal
breast cell line MCF-10A were obtained from the American Type
Culture Collection (ATCC; Manassas, VA). Details of cell maintenance
are found in the supplemental methods.
2.2. Growth assay
Approximately 2×103 cells per well were plated in a 96-well plate
and cells were either treated with the drug at different concentrations
(0.5, 1.0, 5.0, 10.0, and 20.0 μM) or mock treated with the vehicle
(DMSO; Sigma-Aldrich, St. Louis, MO) for 48 h. For long term growth
assay, cells were treated with 2.5 and 5 μM of SL-1-39 or mock-treated
with DMSO for two, three and four days. Cell proliferation was mon-
itored with MTT (Life Technologies, Carlsbad, CA) per manufacturer's
protocol.
2.3. Cell viability and apoptosis assay
The Apolive-Glo™ Multiple Assay (Promega, Sunnyvale, CA) was
used to evaluate cell viability and apoptosis. Cells were plated at
1000 cells per well in a 96-well plate (Corning, Corning, NY) and
treated with one of the following: 5 μM SHetA2, SL-1-39, 10 μM di-
goxin, 100 nM cabazitaxel or mock treated with DMSO. Forty-eight
hours after treatment, analysis was performed per manufacturer's pro-
tocols using a FLUOstar® Omega microplate reader (BMG Lab Tech lnc.,
Cary, NC).
2.4. Bromodeoxyuridine (BrdU) incorporation assay
Approximately 2×105 cells were plated in 6-well plates containing
glass coverslips. Cells were treated with 2.5 or 5 μM SL-1-39 or mock-
treated 24 h later. One hour prior to harvesting the cells (12, 24 and
48 h post-treatment), cells were pulse-labeled with 10 μM BrdU for 1 h.
Cells were fixed with 10% formalin in phosphate buffer saline (PBS),
and BrdU-positive cells were analyzed as previously published [24] and
briefly described in the supplemental methods.
2.5. Protein and gene expression analysis
For protein expression, cells were lysed in buffer containing 0.05M
HEPES, 1% Triton, 0.1% SDS, 0.002M EDTA, 1% deoxycholate, 0.002M
EGTA, 0.15M NaCl, 0.01M NaF, and 1% Halt™ protease inhibitor
cocktail (Thermo-Fisher Scientific, Waltham, MA) and protein expres-
sion was analyzed using western blot analysis. Details of protocol and
list of antibodies are found in the supplemental methods. For gene
expression, total RNA was isolated via Direct-zol RNA kit according to
the manufacturer's protocol (Zymo Research Corporation, Irvine, CA).
RNA was converted to cDNA using oligo-dT18 primers and Moloney
Murine Leukemia Reverse Transcriptase (MMLV-RT; Promega). Gene
expression was monitored via semi-quantitative or quantitative RT-PCR
(qRT-PCR) using Go-Taq Green Master Mix (Promega) or Fast SYBR™
Green Master Mix, respectively (Life Technologies, Carlsbad, CA).
Relative mRNA expression was normalized to GAPDH. All primers were
synthesized by Integrated DNA Technologies, Inc. (San Diego, CA) and
sequences are found in the supplemental methods.
2.6. Immunofluorescence
Approximately 2×105 SKBR3 cells were plated in 6-well plates
containing glass coverslips. The cells were treated with 5 μM SL-1-39 or
mock-treated 24 h later. After 22 h of treatment, cells were exposed to
20 or 50nΜ of Bafilomycin for 2 h. Cells were fixed with 10% formalin
in PBS and permeabilized with 1X PBS +0.5% Triton for 30 min at
room temperature. Slides were blocked with PBS +10% FBS and in-
cubated with anti-Lamp1 (D2D11, Cell Signaling, Danvers, MA) and
anti-HER2 (3B5, Santa Cruz Biotechnology) in PBS for 2 h at 37 °C.
Slides were washed twice with PBS, incubated with Alexa Fluor-con-
jugated secondary antibodies (Life Technologies) for 2 h at room tem-
perature, washed twice with PBS, and mounted with Prolong Gold with
DAPI (Life Technologies). Images were captured at 2048 × 2048 re-
solution on a Zeiss LSM-700 confocal microscope using a 40X oil ob-
jective. For each region of interest, five z-stacks were captured and
subsequently processed with ImageJ (https://imagej.nih.gov/ij/) to
produce z-projections and to adjust brightness and contrast.
2.7. Statistical analysis
All statistical analyses were conducted using GraphPad Prism 6
(Graphpad Software Inc., La Jolla, California). The best-fit IC50 curves
were fitted to one-phase decay or sigmoidal dose-response algorithms.
All results are presented as mean ± SD.
3. Results
3.1. SL-1-39 reduces breast cancer cell proliferation by preventing S-phase
progression
To understand the effects of SL-1-39 on breast cancer, we evaluated
the growth inhibitory activity of SL-1-39 on a panel of breast cancer
cells including MCF7, T47D, MDA-MB-231, MDA-MB-453, MDA-MB-
468, SKBR3, HCC1806 and BT20 (Table 1). Results in Table 1 establish
that SL-1-39 effectively decreased the growth of most breast cancer
cells with an IC50 ranging from 2.20 to 5.53 μM. Amongst the cell lines
tested, the ER-/HER2+ MDA-MB-453 and SKBR3 cells showed the
greatest sensitivities to SL-1-39, with IC50 values of 2.20 ± 1.13 μM
and 2.91 ± 0.91 μM, respectively.
To determine whether the growth inhibitory effects of SL-1-39 were
sustained beyond two days, SKBR3 and MDA-MB-453 were treated with
either 2.5 or 5 μM of SL-1-39 (or mock-treated), and cell growth was
evaluated two, three, and four days after treatment (Fig. 1A–B). Con-
sistent with the data in Table 1, both concentrations of SL-1-39 in-
hibited SKBR3 and MDA-MB-453 cells two days post-treatment, and this
inhibitory effect was sustained for four days without further addition of
the drug. To elucidate how SL-1-39 blocks cell growth, a BrdU in-
corporation assay was used to evaluate SL-1-39's effect on S-phase
progression. Breast cancer cells were treated with 2.5 or 5 μM of SL-1-
39 or mock-treated, pulse-labeled with BrdU for 1 h, and then collected
Table 1
Potency of SL-1-39 in different breast cancer cell lines.
Potency (IC50 values) in μM (mean ± SD).
Breast cancer cell lines Cell type SL-1-39
IC50 values in μM (mean± SD)
MCF7 Luminal-type 5.53± 1.11
T47D Luminal-type 3.06± 1.40
SKBR3 Luminal-type 2.91± 0.91
MDA-MB-453 Luminal-type 2.20± 1.13
MDA-MB-468 Basal-type 3.47± 0.33
MDA-MB-231 Basal-type 5.47± 1.15
HCC1806 Basal-type 5.37± 0.30
BT20 Basal-type 3.41± 1.22
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12, 24, and 48 h after treatment. Cells treated with 2.5 μM and 5 μM of
the analog for 24 h showed not only a decrease in total cell number but
also a decrease in the percentage of cells in S-phase, as noted by the
reduction in BrdU-positive cells (Fig. 1C and D). Quantitative analysis
confirmed that even as early as 12 h the number of SKBR3 cells in S-
phase decreased from 33.8% in mock-treated cells to 21.9% and 17.1%
in cells treated with 2.5 μM (P < 0.05) and 5 μM (P < 0.01) of SL-1-
39, respectively (Fig. 1C). Forty-eight hours after 5 μM SL-1-39 treat-
ment, less than 2% of the SKBR3 cells were in S-phase (P < 0.001).
Similar results were observed in MDA-MB-453 cells, with the
Fig. 1. SL-1-39 reduced ER-negative breast cancer cell proliferation up to 4 days by preventing cells into S phase. SKBR3 (A) and MDA-MB-453 (B) cells were
plated in 96-well plates and treated with 2.5 μM, 5 μM SL-1-39 or mock treated. Relative cell numbers were determined using MTT 2, 3, 4 days after treatment (***,
P < 0.001). SKBR3(C) and MDA-MB-453(D) cells were seeded on coverslips in 6-well plates and treated with 2.5 μM, 5 μM SL-1-39 or mock treated. After 12, 24 and
48 h, cells were stained with BrdU, fixed and then analyzed on a fluorescent microscope. Nuclei were visualized by DAPI staining (in blue). Cells undergoing DNA
synthesis appeared in green (BrdU). Columns represent the percentage of cells in S phase with SD (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Experiments were
repeated at least three times.
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percentage of cells in S-phase decreasing from 43.2% in mock-treated
cells to 25.7% and 15.4% in cells treated for 12 h with 2.5 μM and 5 μM
of SL-1-39, respectively (P < 0.001) (Fig. 1D). After 48 h of 5 μM SL-1-
39 treatment, only 6.2% of the cells were in S-phase (P < 0.001).
MDA-MB-453 and SKBR3 cells were also treated with either SL-1-39
or SHetA2 to evaluate the induction of apoptosis (Fig.S1). A subset of
cells was treated with either digoxin, a Na+/K + ATPase inhibitor, or
cabazitaxel, a chemotherapeutic drug that targets microtubule poly-
merization, to serve as positive controls for apoptosis. As expected, SL-
1-39, SHetA2, digoxin and cabazitaxel reduced MDA-MB-453 and
SKBR3 cell growth by at least 2.5-fold (Fig.S1A and C). However, while
digoxin and cabazitaxel significantly increased activities of caspase 3
and 7, important markers of apoptosis [25,26], SL-1-39 and ShetA2 did
not (Fig. S1B and D). The data suggest that the decrease in growth of
ER-breast cancer cells is associated with an inhibition of cell pro-
liferation, not an increase in apoptosis. We also tested SL-1-39 and
SHetA2 on human mammary epithelial cells (HMECs). Results show
that while these heteroarotinoids do dcrease the growth of HMECs, the
compounds do not induce apoptosis (Fig.S1E and F).
3.2. SL-1-39 decreases the expression of cell cycle regulators
Since SL-1-39 appears to block S-phase progression, the expression
levels of key cell cycle regulators were analyzed in MDA-MB-453 and
SKBR3 cells using western blot analysis (Fig. 2 and Fig.S2). Results
show that in MDA-MB-453 cells, 5 μM of SL-1-39 was sufficient to re-
duce the expression of cyclin A (P < 0.01), cyclin B, cyclin D1, and
cyclin E (P < 0.001) within 12 h of treatment and cdk2 (P < 0.01) by
24 h (Fig. 2-B). These decreases were still observed 48 h after treatment.
Amongst all the cell cycle proteins analyzed, cyclin D1 was the most
impacted, with protein levels dropping by 95% in cells treated with
5 μM of SL-1-39 for 48 h (Fig. 2B).
To determine if a similar decrease is also observed at the mRNA
level, semi-quantitative and quantitative RT-PCR (qRT-PCR) were used
to analyze the transcript levels of cell cycle genes in MDA-MB-453 cells
treated as previously described. Cells treated with SL-1-39 expressed
lower levels of several cell cycle genes at the mRNA level (Fig. 2C–D).
Quantitative RT-PCR data indicate that MDA-MB-453 cells treated with
5 μM of SL-1-39 expressed significantly less cyclin A, B, D1, E, and cdk2
12 h after treatment (32%, 73%, 31%, 83% and 35%, respectively;
P < 0.001; Fig. 2D). Furthermore, the mRNA levels of cyclin B, cyclin
Fig. 2. SL-1-39 reduced the expression of cell cycle regulators. MDA-MB-453 cells were plated in 6-well plates and treated with 2.5 μM, 5 μM SL-1-39 or mock
treated for 12, 24 or 48 h. (A) cyclin A, cyclin B, cyclin D1, cyclin E and CDK2 protein expressions in cell lysates were analyzed with western blot. Actin served as
control. (B) Quantification of western blot, columns represent average protein expression level (with SD) of at least three independent experiments (*, P < 0.05; **,
P < 0.01; ***, P < 0.001). (C) RT-PCR analysis of cyclin A, cyclin B, cyclin D1, cyclin E and CDK2 in total RNA extracted from cell lysates. GAPDH served as
control. (D) Real-time PCR analysis of cyclin A, cyclin B, cyclin D1, cyclin E and CDK2 in total RNA extracted from cell lysates. GAPDH served as control. (***,
P < 0.001).
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D1 and cyclin E were decreased with only 2.5 μM of SL-1-39 12 h after
SL-1-39 treatment (P < 0.001). The inhibitory effects of SL-1-39 on the
cell cycle regulators were also confirmed in SKBR3 cells (Fig.S2A-B),
albeit a more modest effect was observed. Coupled with the growth
data, the results clearly suggest that SL-1-39 inhibits breast cancer cell
growth by decreasing the expression of key cell cycle regulators at both
protein and mRNA levels.
3.3. SL-1-39 reduces HER2 expression and inhibits the EGFR/HER2
signaling pathways
To further investigate the mechanism of action of SL-1-39, western
blot analysis was used to determine the expression of important breast
cancer biomarkers— ERα, PR, AR, EGFR (HER1), HER2, HER3 and
HER4— in all the breast cancer cell lines previously found to respond to
SL-1-39 treatment (Fig. 3A). This analysis confirmed the following:
MCF7, T47D and BT474 are ERα+; T47D, SKBR3, MDA-MB-453 and
BT474 are HER2+; and MDA-MB-468, MDA-MB-231, HCC1806 and
BT20 are ERα-, PR-, and HER2- (triple negative breast cancer cell lines).
For each cell line, the expression status of each biomarker was com-
pared to its SL-1-39 response using IC50 values (Fig. 3B). Interestingly,
cells expressing HER2 collectively exhibited a greater sensitivity to-
wards SL-1-39. T-47D, SKBR3, MDA-MB-453 and BT474 all express
HER2, and the IC50 values are 3.06 ± 1.40 μM, 2.91 ± 0.91 μM,
2.20 ± 1.13 μM and 2.39 ± 0.28 μM, respectively. The correlation of
HER2 expression to IC50 suggests that SL-1-39-mediated growth in-
hibition may involve modulating the HER2/EGFR signaling pathway.
To determine whether the HER2/EGFR pathway plays a role in
mediating the effects of SL-1-39, we analyzed the protein expression
status of HER2 and its downstream effectors, MAPK and Akt in MDA-
Fig. 3. SL-1-39 response is associated with HER2 expression. (A) Receptor expression (ERα, PR, AR, EGFR, HER2, HER3, HER4) in total cell lysates (MCF7, T47D,
SKBR3, MDA-MB-453, BT474, MDA-MB-468, MDA-MB-231, HCC1806 and BT20) were analyzed with western blot. Actin served as control. (B) Breast cancer cell
lines with their SL-1-39 response and expression status of biomarkers.
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MB-453 cells treated with SL-1-39. Western blot data in Fig. 4A and B
shows that in MDA-MB-453 cells a 36.7% decrease in HER2 protein
expression occurred within 12 h of 5 μM SL-1-39 treatment; and after
48 h of treatment, the expression dropped 86.4% compared to control.
Consistent with this observation, the level of phosphorylated MAPK, an
important downstream effector of the HER2/EGFR signaling pathway,
also showed significant reduction at 12 h, while the total MAPK level
did not significantly decrease until 48 h.
After confirming that SL-1-39 reduces HER2 expression and MAPK
phosphorylation in MDA-MD-453 cells, we questioned whether other
HER2 positive breast cancer cells (SKBR3, T-47D and BT-474) have a
similar response to SL-1-39. Consistent with the results seen in MDA-
MB-453 cells, SKBR3, T-47D and BT-474 also exhibited lower expres-
sion of HER2 and pMAPK, particularly after 24 and 48 h of SL-1-39
treatment, while the total MAPK did not show any significant change
(Fig. 4C and E, and Fig. S3). Quantification of western blots confirmed
that after 24 h of 5 μM treatment of SKBR3 and T47D cells, HER2
protein levels dropped to 33.7% and 58.4% respectively, while the re-
lative ratio of pMAPK to total MAPK was reduced by 36.9% and 54.3%,
respectively (P < 0.01, Fig. 4D and F). Interestingly, SKBR3 exhibited
only moderate levels of HER2 down-regulation though it has the
highest HER2 expression, while T47D, with its lower level of HER2
expression, showed a more significant reduction.
To evaluate whether the decrease in HER2 and P-MAPK expression
occurred earlier than 12 h, MDA-MB-453 cells were treated with 5 μM
SL-1-39 and collected at 2, 4, 8, 12 and 24 h after treatment (Fig. 5A).
Similar experiments were carried out on SKBR3, which is amplified in
HER2 (data not shown). Results in Fig. 5A show a reduction in both
HER2 and the active phosphorylated form, P-HER2, as early as 2 h after
treatment. Again, while the total expression of MAPK did not sig-
nificantly change, levels of P-MAPK were dramatically reduced by
70.1% just 2 h after treatment (P < 0.001). We also analyzed Akt,
another downstream kinase of the HER2 pathway; and results indicate
that although total Akt levels did not show a significant decrease (ex-
cept for a transient decrease 2 h after treatment), P-Akt levels were
decreased by 93.7% 2 h after treatment (P < 0.001). Given that ex-
pression of total HER2 and phosphorylated HER2 were reduced si-
multaneously by SL-1-39, we deduced that the down-regulation of total
HER2, rather than merely a decrease in phosphorylation, was the pri-
mary effect of SL-1-39. To examine whether the changes in total HER2
expression were due to alterations at the transcriptional level, qRT-PCR
was used to evaluate the transcript levels of HER2 in MDA-MB-453 cells
Fig. 4. SL-1-39 decreased HER2 expression and phosphorylation of HER2 downstream effectors. Cells were plated in 6-well plates and treated with 2.5 μM,
5 μM SL-1-39 or mock treated for 12, 24 or 48 h. HER2, P-MAPK, MAPK, P-Akt, Akt protein expressions in MDA-MB-453 (A), SKBR3 (C), T47D (E) cells were analyzed
with western blots. Actin served as control. Quantification of HER2 expression and average ratio of P-MAPK/total MAPK were analyzed in MDA-MB-453 (B), SKBR3
(D), T47D (F) cells, data represent at least three independent experiments (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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treated as previously mentioned. Results show that there were no sig-
nificant changes in HER2 mRNA levels even after 24 h of treatment with
5 μM of SL-1-39 (Fig. 5B), indicating that any changes in HER2 ex-
pression must occur post-transcriptionally.
3.4. SL-1-39 decreases HER2 levels through lysosomal degradation
In order to determine whether the decrease in HER2 levels is as-
sociated with proteasomal degradation, we blocked the function of the
proteasome with varying concentrations of MG132 following treatment
of MDA-MB-453 cells with 5 μM SL-1-39. HER2 protein expression was
reduced by 42% when treated with SL-1-39 alone, but the presence of
MG132 did not restore the decreased HER2 expression induced by SL-1-
39 (Fig. 6A); whereas the expression of β-catenin, a protein known to be
degraded via the proteasome, was restored in a concentration-depen-
dent manner. This was repeated with another proteasome inhibitor,
ALLN, and results were consistent with the MG132 data (Fig.S4).
However, when SKBR3 cells were treated with a lysosomal inhibitor
bafilomycin (BAF) after SL-1-39 treatment, HER2 expression was re-
stored in a concentration-dependent manner, as was β-catenin (Fig. 6B).
Specifically, 20 nM BAF was sufficient to return HER2 protein levels to
that of control cells. To further support the notion that SL-1-39 reduces
HER2 expression via lysosomal degradation, immunofluorescence
microscopy was used to monitor HER2 expression after SL-1-39 treat-
ment in the presence and absence of BAF. As shown in Fig. 6C, im-
munolabeled HER2 protein levels are reduced after SL-1-39 treatment
in comparison to control cells. Consistent with the western blot data,
immunofluorescence of HER2 protein levels revealed that both 20 nM
and 50 nM BAF was sufficient to restore HER2 protein to normal levels
in cells previously treated with SL-1-39 (Fig. 6C).
We considered that if HER2 is being degraded by the lysosome, the
protein would be trafficked to this organelle, and HER2 would colo-
calize with LAMP1, a resident lysosomal marker. Interestingly, none of
our experiments showed any colocalization of LAMP1 with HER2.
Instead, HER2 was only detected at the cell surface, even when total
HER2 expression levels were markedly reduced by treatment with SL-1-
39. These data are consistent with a model in which HER2 does traffic
to the lysosome for degradation, but that the HER2 epitope recognized
by the antibody is highly sensitive to lysosomal degradation, which
makes concomitant detection of HER2 and LAMP1 difficult.
4. Discussion
One of the most widely used HER2-targeted therapies is trastu-
zumab, a monoclonal antibody that binds to and blocks HER2 dimer-
ization, which promotes its degradation via endocytic receptor
Fig. 5. Early decrease in HER2, pMAPK and pAkt expression induced by SL-1-39 is independent of mRNA transcription. (A) MDA-MB-453 cells were plated in
6-well plates and treated with 5 μM SL-1-39 for 2, 4, 8, 12, 24 h. HER2, p-MAPK, MAPK, p-Akt, Akt protein expressions were analyzed with western blots. Actin
served as control. Quantification of western blot was performed, in which columns represent average protein expression level (with SD; *, P < 0.05; **, P < 0.01;
***, P < 0.001). (B) MDA-MB-453 cells were plated in 6-well plates and treated with 2.5 μM, 5 μM SL-1-39 or mock treated for 12 or 24 h. Real-time PCR analysis of
HER2 (P > 0.05) in total RNA extracted from cell lysates were performed. GAPDH served as control.
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degradation [27,28]. This in turn induces the accumulation of the cy-
clin-dependent kinase inhibitor (CKI) p27 to promote cell cycle arrest
[29–31]. Although patients with HER2+ breast cancer generally show
a positive response to trastuzumab, multiple studies indicate that re-
lapse often occurs after prolonged treatment [9,32]. The development
of acquired resistance is often associated with mutations that: (1) pre-
vent trastuzumab binding; (2) upregulate HER2 downstream signaling
pathways; (3) enhance signaling through alternate pathways; or (4) fail
to trigger immune-mediated mechanisms to destroy tumor cells
[33–35]. The development of resistance highlights the need to develop
new therapeutic options aimed at improving outcomes of patients with
HER2+ breast cancer.
SHetA2, one of the original Flex-Hets, exhibited promising growth
inhibitory effects across multiple cancer types [17,19,20,22]. Previous
Fig. 6. SL-1-39 induced HER2 down-
regulation through lysosomal de-
gradation. (A) MDA-MB-453 cells were
plated in 6-well plates and treated with
5 μM SL-1-39 for 22 h then exposed
with proteasome inhibitor, MG-132 for
2 h. HER2, beta-catenin protein ex-
pressions were analyzed with western
blots. Actin served as control. (B–C)
SKBR3 cells were treated with 5mM SL-
1-39 or mock treated. After 22 h, SL1-
39 treated cells were exposed to 20 or
50 nM of bafilomycin for 2 h. (B) Cells
were collected for western blot analysis
or (C) fixed and analyzed on a fluor-
escent microscope. Nuclei were visua-
lized by DAPI staining (in blue), HER2
and LAMP1 were stained in white and
green, respectively. Scale bars represent
20 μm.
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studies have demonstrated that SHetA2 can induce G1 cell cycle arrest
by promoting proteasomal degradation of cyclin D1 in both ovarian and
kidney cancer cells [36–38]. SHetA2 has also been shown to target the
mitochondria, altering the expression of Bcl-2, caspase 3, and PARP-1
protein, subsequently leading to mitochondrial swelling and ultimately
apoptosis [36,38,39]. A study carried out by Myers et al. found that
SHetA2 is likewise capable of inhibiting angiogenesis in cancer cells
[21]. Furthermore, numerous studies have reported on the relatively
low to no toxicity of SHetA2, even at concentrations far exceeding its
effective dose [36,40,41]. However, as the utility of SHetA2 is limited
by its high lipophilicity (logP) [22], 2nd generation SHetA2 analogs
were designed and synthesized to achieve a lower logP value by mod-
ifying the structure of the thiochromane ring while retaining the ni-
trophenyl group and the thiourea linker [22].
In this current study, we not only demonstrated the growth-in-
hibitory effects of the 2nd generation analog SL-1-39 on the HER2+
breast cancer cells, MDA-MB-453 and SKBR3 (Table 1), but we also
demonstrated that the decrease in cell number was associated with an
interruption of cell cycle progression through the down-regulation of
multiple key cell cycle regulators, such as cyclin A and D1. These ob-
servations are consistent with previous studies carried out on the par-
ental drug, SHetA2, and another 2nd generation analog, SL-1-18, both
of which have been shown to decrease cyclin D1 expression and sub-
sequently arrest cells at the G1 phase [24,36,37]. We speculate that the
post-transcriptional decrease in cyclin D1 levels (see Fig. 2) is likely
attributed to reduction in MAPK activity mediated by SL-1-39 treat-
ment. Alternatively, as seen with SL-1-18, SL-1-39 may increase the
degradation of the cyclin D1 protein via the proteasome and/or lyso-
some, although this was not observed in any of the MG132 or BAF
experiments (data not shown).
The most notable results presented in this study demonstrate that
SL-1-39 reduces protein expression of HER2 by inducing lysosomal
degradation (Figs. 4–6). In the HER2+ breast cancer cell lines MDA-
MB-453, SKBR3, T47D, and BT-474, SL-1-39 decreased HER2 protein
expression and the HER2-associated phosphorylation of MAPK in a
time-dependent manner (Figs. 4–5). Though HER2 protein levels de-
creased within 2 h of exposure (Fig. 5), HER2 mRNA levels remained
unchanged, suggesting that the decrease in HER2 is associated with
degradation of the HER2 protein. Curiously, we found that cells with
lower levels of HER2 (e.g. T47D) were more sensitive to SL-1-39-in-
duced HER2 degradation than cells with high levels of HER2 (e.g.
SKBR3).
This is the first study to show that a flexible heteroarotinoid analog
can target the HER2 signaling pathway, and our results suggest that this
decrease is associated with the lysosomal degradation pathway. Such a
finding is not completely without precedence, as other anti-HER2
agents, including trastuzumab, are known to bind selectively to the
extracellular domain of HER2 and promote HER2 degradation by re-
ceptor-mediated endocytosis into the lysosome [29,42,43]. How SL-1-
39 triggers the lysosomal degradation pathway remains unclear.
However, we speculate that since the normal turnover of most plasma
membrane receptors requires lysosomal targeting via the ubiquitination
pathway [44], and HER2 has been shown in previous studies to undergo
ubiquitin-dependent lysosomal degradation [45–47], SL-1-39 may in-
itiate degradation of HER2 by triggering its ubiquitination. This sup-
position is further supported by our recently published study on the
sister compound, SL-1-18, which promotes the ubiquitination and
subsequent degradation of the cytoplasmic receptor ERα.
The observation that SL-1-39 down-regulates HER2 faster than
trastuzumab (2 vs. 24 h, respectively) [48–51] is quite promising.
Especially intriguing is the idea that SL-1-39 might be an effective
therapeutic against certain trastuzumab-resistant breast cancers, parti-
cularly those that are associated with a truncated HER2 (p95-HER2) or
ERBB2 mutations [52]. Since SL-1-39 works intracellularly, the lack of
an extracellular domain in p95-HER2 should have little to no effect on
its activity. Similarly, the most common ERBB2 mutations in breast
cancer patients do not affect the HER2 ubiquitination docking site,
tyrosine-1112, which allows the polyubiquitination of HER2 via the E3
ubiquitin ligase (i.e. c-Cbl) [45]. In short, our encouraging findings
warrant further development of SL-1-39 as a potential therapeutic for
HER2+ breast cancer.
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